Literature DB >> 16614850

RNAi-mediated knockdown of aldehyde dehydrogenase class-1A1 and class-3A1 is specific and reveals that each contributes equally to the resistance against 4-hydroperoxycyclophosphamide.

Jan S Moreb1, Dagmara Mohuczy, Dagmara Muhoczy, Blanca Ostmark, James R Zucali.   

Abstract

PURPOSE: Aldehyde dehydrogenases class-1A1 (ALDH1A1) and class-3A1 (ALDH3A1) have been associated with resistance to cyclophosphamide (CP) and its derivatives. We have previously reported the downregulation of these enzymes by all-trans retinoic acid (ATRA).
METHODS: In this study, we used siRNA duplexes as well as retrovirally expressed siRNA to knockdown one or both enzymes together in A549 lung cancer cell line in order to investigate the role of each one in mediating the resistance and the effect of the addition of ATRA.
RESULTS: The results show that significant and specific knockdown of each enzyme can be achieved and that each one contributes similarly to cell resistance to 4-hydroperoxycyclophosphamide (4-HC), an active derivative of CP. Added effects were seen when both enzymes were inhibited. The addition of ATRA also exhibited additional inhibitory effects on ALDH activity and increased 4-HC toxicity when added to single siRNA aimed at one of the enzymes. On the other hand, ATRA had minimal and insignificant additional inhibitory effects on ALDH enzyme activity when added to a combination of siRNAs against both enzymes, but still increased 4-HC toxicity beyond that seen with RNAi-mediated inhibition of both enzymes together.
CONCLUSIONS: We conclude that both enzymes, ALDH1A1 and ALDH3A1 will need to be blocked in order to achieve the highest sensitivity to 4-HC. Furthermore, ATRA increases 4-HC toxicity even when added to a combination of siRNAs against both enzymes, thus suggesting additional mechanisms by which ATRA can increase drug toxicity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16614850     DOI: 10.1007/s00280-006-0233-6

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  53 in total

1.  The enzymatic activity of human aldehyde dehydrogenases 1A2 and 2 (ALDH1A2 and ALDH2) is detected by Aldefluor, inhibited by diethylaminobenzaldehyde and has significant effects on cell proliferation and drug resistance.

Authors:  Jan S Moreb; Deniz Ucar; Shuhong Han; John K Amory; Alex S Goldstein; Blanca Ostmark; Lung-Ji Chang
Journal:  Chem Biol Interact       Date:  2011-11-03       Impact factor: 5.192

2.  Discovery of a novel class of covalent inhibitor for aldehyde dehydrogenases.

Authors:  May Khanna; Che-Hong Chen; Ann Kimble-Hill; Bibek Parajuli; Samantha Perez-Miller; Sulochanadevi Baskaran; Jeewon Kim; Karl Dria; Vasilis Vasiliou; Daria Mochly-Rosen; Thomas D Hurley
Journal:  J Biol Chem       Date:  2011-10-21       Impact factor: 5.157

Review 3.  The role of human aldehyde dehydrogenase in normal and cancer stem cells.

Authors:  Irene Ma; Alison L Allan
Journal:  Stem Cell Rev Rep       Date:  2011-06       Impact factor: 5.739

4.  Design, synthesis, and ex vivo evaluation of a selective inhibitor for retinaldehyde dehydrogenase enzymes.

Authors:  Angelica R Harper; Anh T Le; Timothy Mather; Anthony Burgett; William Berry; Jody A Summers
Journal:  Bioorg Med Chem       Date:  2018-10-24       Impact factor: 3.641

5.  Discovery of a series of aromatic lactones as ALDH1/2-directed inhibitors.

Authors:  Cameron D Buchman; Krishna K Mahalingan; Thomas D Hurley
Journal:  Chem Biol Interact       Date:  2015-01-29       Impact factor: 5.192

6.  Inhibition of the Aldehyde Dehydrogenase 1/2 Family by Psoralen and Coumarin Derivatives.

Authors:  Cameron D Buchman; Thomas D Hurley
Journal:  J Med Chem       Date:  2017-03-06       Impact factor: 7.446

7.  Metronomic cyclophosphamide schedule-dependence of innate immune cell recruitment and tumor regression in an implanted glioma model.

Authors:  Junjie Wu; David J Waxman
Journal:  Cancer Lett       Date:  2014-07-25       Impact factor: 8.679

8.  Aldehyde dehydrogenase activity as a functional marker for lung cancer.

Authors:  Deniz Ucar; Christopher R Cogle; James R Zucali; Blanca Ostmark; Edward W Scott; Robert Zori; Brian A Gray; Jan S Moreb
Journal:  Chem Biol Interact       Date:  2008-10-05       Impact factor: 5.192

Review 9.  Targeting cancer stem cell-specific markers and/or associated signaling pathways for overcoming cancer drug resistance.

Authors:  Peyman Ranji; Tayyebali Salmani Kesejini; Sara Saeedikhoo; Ali Mohammad Alizadeh
Journal:  Tumour Biol       Date:  2016-08-26

10.  ALDH isozymes downregulation affects cell growth, cell motility and gene expression in lung cancer cells.

Authors:  Jan S Moreb; Henry V Baker; Lung-Ji Chang; Maria Amaya; M Cecilia Lopez; Blanca Ostmark; Wayne Chou
Journal:  Mol Cancer       Date:  2008-11-24       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.